

SCIENCE OF
POSSIBILITY
At Vertex, we invest in scientific innovation to create transformative medicines for people with serious diseases.
Vertex receives FDA approval for our first CF medicine for eligible children with cystic fibrosis ages 1 to <4 months
Vertex receives FDA approval for our fourth medicine for eligible children with cystic fibrosis ages 2 to 5 years
Vertex announces first quarter 2023 financial results
Vertex is pleased to release its 2022 Corporate Responsibility Report
We’ve completed submission of our rolling Biologics License Applications (BLAs) to the U.S. FDA for our potential treatment for sickle cell disease and beta thalassemia
Working at Vertex
Working at Vertex
Our company is built on an inclusive culture that brings together the best and brightest in every field striving for one goal: to improve the lives of people with serious diseases.

Featured Stories